Literature DB >> 26296679

Clinical characteristics of patients with relapsed multiple myeloma.

Meletios A Dimopoulos1, Evangelos Terpos2, Ruben Niesvizky3, Antonio Palumbo4.   

Abstract

Although survival outcomes have improved over the last decade for patients with multiple myeloma (MM), few patients remain free of disease and most inevitably relapse. Selecting a treatment for patients with relapsed MM is challenging given the number and diversity of regimens patients may have previously received, which can affect subsequent therapeutic choices. Importantly, a number of patient- and disease-related factors can also have an effect on treatment choice, treatment efficacy, and tolerability; thus, an understanding of the heterogeneity of patients in the setting of relapsed MM is important for appropriate treatment selection. Here, we review select patient and disease characteristics reported in key interventional and observational studies in relapsed MM (including age, sex, race, and the presence of high-risk disease, renal impairment, or peripheral neuropathy at baseline) to examine common and disparate features of patients with relapsed MM. As therapeutic regimens can have varying efficacy and/or tolerability in patients depending on these factors, we also provide treatment recommendations for patients with select baseline characteristics.
Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Immunomodulatory drug; Multiple myeloma; Proteasome inhibitor

Mesh:

Substances:

Year:  2015        PMID: 26296679     DOI: 10.1016/j.ctrv.2015.07.005

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


  13 in total

1.  Low serum vitamin D occurs commonly among multiple myeloma patients treated with bortezomib and/or thalidomide and is associated with severe neuropathy.

Authors:  James Wang; Kyle A Udd; Aleksandra Vidisheva; Regina A Swift; Tanya M Spektor; Eric Bravin; Emad Ibrahim; Jonathan Treisman; Mohammed Masri; James R Berenson
Journal:  Support Care Cancer       Date:  2016-02-23       Impact factor: 3.603

2.  Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR.

Authors:  Katja Weisel; Maria-Victoria Mateos; Francesca Gay; Michel Delforge; Gordon Cook; Zsolt Szabo; Renaud Desgraz; Lucy DeCosta; Philippe Moreau
Journal:  Leukemia       Date:  2020-10-16       Impact factor: 11.528

Review 3.  Towards Stratified Medicine in Plasma Cell Myeloma.

Authors:  Philip Egan; Stephen Drain; Caroline Conway; Anthony J Bjourson; H Denis Alexander
Journal:  Int J Mol Sci       Date:  2016-10-21       Impact factor: 5.923

Review 4.  Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date.

Authors:  Katja Weisel
Journal:  Onco Targets Ther       Date:  2016-10-05       Impact factor: 4.147

5.  Incidence and risk of hypertension in patients newly treated for multiple myeloma: a retrospective cohort study.

Authors:  Ajai Chari; Khalid Mezzi; Shao Zhu; Winifred Werther; Diana Felici; Alexander R Lyon
Journal:  BMC Cancer       Date:  2016-11-22       Impact factor: 4.430

6.  Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.

Authors:  Shaji Kumar; Philippe Moreau; Parameswaran Hari; Maria-Victoria Mateos; Heinz Ludwig; Chaim Shustik; Tamas Masszi; Andrew Spencer; Roman Hájek; Kenneth Romeril; Irit Avivi; Anna M Liberati; Monique C Minnema; Hermann Einsele; Sagar Lonial; Deborah Berg; Jianchang Lin; Neeraj Gupta; Dixie-Lee Esseltine; Paul G Richardson
Journal:  Br J Haematol       Date:  2017-05-09       Impact factor: 6.998

7.  Novel risk stratification algorithm for estimating the risk of death in patients with relapsed multiple myeloma: external validation in a retrospective chart review.

Authors:  Roman Hájek; Sebastian Gonzalez-McQuire; Zsolt Szabo; Michel Delforge; Lucy DeCosta; Marc S Raab; Walter Bouwmeester; Marco Campioni; Andrew Briggs
Journal:  BMJ Open       Date:  2020-07-14       Impact factor: 2.692

8.  A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma.

Authors:  Jesús F San-Miguel; Maria-Asunción Echeveste Gutierrez; Ivan Špicka; María-Victoria Mateos; Kevin Song; Michael D Craig; Joan Bladé; Roman Hájek; Christine Chen; Alessandra Di Bacco; Jose Estevam; Neeraj Gupta; Catriona Byrne; Vickie Lu; Helgi van de Velde; Sagar Lonial
Journal:  Haematologica       Date:  2018-06-28       Impact factor: 9.941

9.  Lenalidomide and Low Dose Dexamethasone Plus Elotuzumab or Carfilzomib for Relapsed or Refractory Multiple Myeloma: A Comparison of Progression-Free Survival with Reconstructed Individual Participant Data.

Authors:  Shuo Li; Xiang-Yu Meng; Souraka Tapara Dramani Maman; Yong-Nong Xiao; Sheng Li
Journal:  Biomed Res Int       Date:  2018-12-16       Impact factor: 3.411

10.  Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma.

Authors:  Roman Hájek; Michel Delforge; Marc S Raab; Paul Schoen; Lucy DeCosta; Ivan Spicka; Jakub Radocha; Ludek Pour; Sebastian Gonzalez-McQuire; Walter Bouwmeester
Journal:  Br J Haematol       Date:  2019-08-06       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.